American Diabetes Association– tag –
-
Dexcom’s Investment Outlook Brightens as G7 CGM Gains Expanded Reimbursement for Type 2 Non-Insulin Diabetes Patients
Seeking Alpha USA Overview Dexcom's investment thesis has significantly improved following expanded insurance reimbursement for its G7 continuous glucose monitoring (CGM) systems, now covering a large population of type 2 non-insulin dia... -
UnitedHealthcare Updates CGM and Insulin Delivery Coverage Policy: Non-Invasive CGMs Excluded Due to Lack of Evidence
UHC Provider Portal (UnitedHealthcare) USA Overview UnitedHealthcare (UHC) has updated its medical policy regarding coverage for continuous glucose monitoring (CGM) and insulin delivery systems for diabetes management. The updated policy... -
CGM Metrics Outperform HbA1c in Assessing Severe Hypoglycemia and DKA Risk in Type 1 Diabetes: ADA-Published Pooled Analysis Reveals
Diabetes Care (American Diabetes Association) USA Overview A pooled analysis of 10 studies involving 1,550 Type 1 diabetes patients, published in the American Diabetes Association's 'Diabetes Care,' revealed that continuous glucose monit... -
ADA 2026: CGM Applications Expand to Type 2 Diabetes; Continuous Ketone Monitoring and Dual Sensors Advance DKA Prevention
Pharmacy Times USA Overview The 86th American Diabetes Association (ADA) Scientific Sessions in 2026 highlighted a significant expansion of continuous glucose monitoring (CGM) beyond intensive insulin management to a broader Type 2 diabe... -
Senseonics Presents Eversense 365 Real-World Data at ADA Scientific Sessions, Highlights 180-Day Wear for Unmet CGM Needs
Peninsula Fly Fishers USA Overview Senseonics Holdings presented real-world evidence for its Eversense 365 implantable continuous glucose monitoring (CGM) system during the American Diabetes Association (ADA)'s 86th Scientific Sessions. ... -
Dexcom Reaffirms CGM Benefits for All People with Diabetes, Expands to Preventive Care with Stelo App Relaunch and Nutrisense Acquisition at ADA 2026
DexCom, Inc. USA Overview Dexcom announced favorable results from the CONNECT randomized controlled trial at ADA 2026, reaffirming CGM's benefits for non-insulin using type 2 diabetes patients. The company also launched early access to i... -
Glucotrack to Showcase Implantable Continuous Blood Glucose Monitoring with 3-Year Lifespan at ADA Sessions
MarketScreener USA Overview Glucotrack is poised to highlight its innovative implantable Continuous Blood Glucose Monitoring (CBGM) technology at the American Diabetes Association's 2026 Scientific Sessions. The Glucotrack CBGM system of...
1